OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Jul 21, 2023;24 (14):

Mouse Models for HTLV-1 Infection and Adult T Cell Leukemia.

Shinsuke Nakajima, Kazu Okuma
Author Information
  1. Shinsuke Nakajima: Department of Microbiology, Faculty of Medicine, Kansai Medical University, Hirakata 573-1010, Osaka, Japan. ORCID
  2. Kazu Okuma: Department of Microbiology, Faculty of Medicine, Kansai Medical University, Hirakata 573-1010, Osaka, Japan. ORCID
PMID: 37511495 DOI: 10.3390/ijms241411737

Abstract

Adult T cell leukemia (ATL) is an aggressive hematologic disease caused by human T cell leukemia virus type 1 (HTLV-1) infection. Various animal models of HTLV-1 infection/ATL have been established to elucidate the pathogenesis of ATL and develop appropriate treatments. For analyses employing murine models, transgenic and immunodeficient mice are used because of the low infectivity of HTLV-1 in mice. Each mouse model has different characteristics that must be considered before use for different HTLV-1 research purposes. HTLV-1 and transgenic mice spontaneously develop tumors, and the roles of both Tax and HBZ in cell transformation and tumor growth have been established. Severely immunodeficient mice were able to be engrafted with ATL cell lines and have been used in preclinical studies of candidate molecules for the treatment of ATL. HTLV-1-infected humanized mice with an established human immune system are a suitable model to characterize cells in the early stages of HTLV-1 infection. This review outlines the characteristics of mouse models of HTLV-1 infection/ATL and describes progress made in elucidating the pathogenesis of ATL and developing related therapies using these mice.

Keywords

ATL HBZ HTLV-1 Tax humanized mouse immunodeficient mouse

References

  1. Arch Virol. 2014 Jul;159(7):1849-56 [PMID: 24818712]
  2. Clin Exp Immunol. 2009 Jul;157(1):104-18 [PMID: 19659776]
  3. Cells. 2021 Sep 23;10(10): [PMID: 34685494]
  4. Blood. 2009 Feb 5;113(6):1287-93 [PMID: 18948574]
  5. Blood. 2005 Dec 15;106(13):4294-302 [PMID: 16118323]
  6. Int J Oncol. 2016 Oct;49(4):1713-21 [PMID: 27499015]
  7. Br J Haematol. 1991 Nov;79(3):428-37 [PMID: 1751370]
  8. Cancer Lett. 2007 Nov 18;257(2):206-15 [PMID: 17764832]
  9. Arthritis Rheum. 1993 Nov;36(11):1612-20 [PMID: 8240438]
  10. J Virol. 2001 Mar;75(5):2185-93 [PMID: 11160722]
  11. PLoS Pathog. 2016 Jan 06;12(1):e1005372 [PMID: 26735971]
  12. Oncotarget. 2017 Aug 27;8(41):69250-69263 [PMID: 29050201]
  13. Front Microbiol. 2023 Feb 02;14:1101544 [PMID: 36819050]
  14. Stem Cells. 2007 Apr;25(4):1003-12 [PMID: 17185612]
  15. Blood. 2004 Nov 15;104(10):3305-11 [PMID: 15292059]
  16. Retrovirology. 2014 Jun 02;11:43 [PMID: 24890041]
  17. PLoS Pathog. 2011 Feb 10;7(2):e1001274 [PMID: 21347344]
  18. J Clin Oncol. 2012 Mar 10;30(8):837-42 [PMID: 22312108]
  19. J Virol. 2018 Jan 30;92(4): [PMID: 29212930]
  20. Immunol Today. 1995 Nov;16(11):529-33 [PMID: 7495490]
  21. Blood. 2008 Nov 1;112(9):3788-97 [PMID: 18689544]
  22. Cancer Res. 2014 Jan 1;74(1):188-200 [PMID: 24177179]
  23. Haematologica. 2022 Dec 01;107(12):2928-2943 [PMID: 35615924]
  24. AIDS Res Hum Retroviruses. 2010 May;26(5):593-603 [PMID: 20438380]
  25. N Engl J Med. 1995 Jun 29;332(26):1744-8 [PMID: 7760890]
  26. J Exp Med. 2010 Dec 20;207(13):2785-92 [PMID: 21135137]
  27. PLoS Pathog. 2018 Mar 22;14(3):e1006933 [PMID: 29566098]
  28. AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1647-51 [PMID: 11080805]
  29. PLoS Pathog. 2023 Feb 2;19(2):e1011104 [PMID: 36730466]
  30. J Infect Dis. 1995 Oct;172(4):974-82 [PMID: 7561218]
  31. Invest New Drugs. 2021 Apr;39(2):317-329 [PMID: 32959166]
  32. J Immunol. 2015 Apr 1;194(7):3513-25 [PMID: 25712215]
  33. Science. 1987 Sep 11;237(4820):1340-3 [PMID: 2888191]
  34. Front Microbiol. 2012 Sep 10;3:322 [PMID: 22973265]
  35. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2390-5 [PMID: 21262803]
  36. Front Microbiol. 2012 Nov 15;3:388 [PMID: 23162541]
  37. Retrovirology. 2019 Dec 16;16(1):41 [PMID: 31843020]
  38. Clin Exp Immunol. 2008 Nov;154(2):270-84 [PMID: 18785974]
  39. J Exp Med. 2009 Jun 8;206(6):1423-34 [PMID: 19487422]
  40. Int J Cancer. 2007 Nov 15;121(10):2205-11 [PMID: 17657714]
  41. J Immunol. 2005 May 15;174(10):6477-89 [PMID: 15879151]
  42. Blood. 1977 Sep;50(3):481-92 [PMID: 301762]
  43. Blood. 2015 Aug 27;126(9):1095-105 [PMID: 26063164]
  44. Blood. 2010 Nov 11;116(19):3809-17 [PMID: 20647569]
  45. Virology. 1993 Sep;196(1):309-18 [PMID: 8356801]
  46. Int J Oncol. 2017 Aug;51(2):633-643 [PMID: 28586006]
  47. J Biol Chem. 2005 Oct 21;280(42):35713-22 [PMID: 16105841]
  48. Blood. 2002 Nov 1;100(9):3175-82 [PMID: 12384415]
  49. Nutr Cancer. 2005;52(2):189-201 [PMID: 16201850]
  50. Cancer Res. 1990 Sep 1;50(17 Suppl):5687S-5691S [PMID: 2167165]
  51. Int J Cancer. 2004 Apr 20;109(4):559-67 [PMID: 14991578]
  52. Sci Signal. 2011 Dec 06;4(202):ra85 [PMID: 22155789]
  53. J Immunol. 1985 Jun;134(6):3798-801 [PMID: 3989296]
  54. J Virol. 1989 Jul;63(7):3185-9 [PMID: 2724422]
  55. Virology. 1993 Nov;197(1):196-204 [PMID: 8212554]
  56. Lancet. 1985 Aug 24;2(8452):407-10 [PMID: 2863442]
  57. J Biol Chem. 2009 Feb 13;284(7):4658-66 [PMID: 19059914]
  58. Blood. 2011 Mar 17;117(11):3076-86 [PMID: 21252091]
  59. Front Immunol. 2022 Jul 25;13:954077 [PMID: 35958554]
  60. Leuk Res. 2011 Nov;35(11):1491-7 [PMID: 21802726]
  61. Blood. 2001 Aug 15;98(4):1200-8 [PMID: 11493471]
  62. Leukemia. 2011 Apr;25(4):575-87 [PMID: 21242994]
  63. Front Microbiol. 2012 Nov 09;3:389 [PMID: 23162542]
  64. Mol Cell Biol. 1991 Oct;11(10):5222-8 [PMID: 1922042]
  65. Br J Haematol. 2022 Sep;198(6):983-987 [PMID: 35607839]
  66. Int Immunol. 2012 Apr;24(4):243-52 [PMID: 22402880]
  67. Blood. 2005 May 15;105(10):4143-5 [PMID: 15665110]
  68. Br J Haematol. 2007 Feb;136(3):424-32 [PMID: 17233845]
  69. Hokkaido Igaku Zasshi. 1991 Jul;66(4):534-43 [PMID: 1916630]
  70. PLoS One. 2011;6(5):e19826 [PMID: 21611197]
  71. J Pathol. 1998 Oct;186(2):209-14 [PMID: 9924438]
  72. Science. 1988 Sep 23;241(4873):1632-9 [PMID: 2971269]
  73. Stem Cells. 2006 Dec;24(12):2840-50 [PMID: 16945998]
  74. Sci Rep. 2016 Jun 02;6:27150 [PMID: 27250643]
  75. Science. 1987 Sep 11;237(4820):1324-9 [PMID: 2888190]
  76. Immunity. 2005 Jun;22(6):729-36 [PMID: 15963787]
  77. J Virol. 2003 May;77(9):5286-94 [PMID: 12692230]
  78. Blood. 1993 Oct 15;82(8):2501-9 [PMID: 8400297]
  79. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [PMID: 6261256]
  80. Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1269-E1278 [PMID: 29358408]
  81. Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21783-8 [PMID: 19966223]
  82. Blood. 2008 Apr 15;111(8):4293-6 [PMID: 18270327]
  83. Viruses. 2011 Jul;3(7):1041-1058 [PMID: 21994769]
  84. Front Immunol. 2018 Jan 17;8:2017 [PMID: 29387068]
  85. Oncotarget. 2016 Aug 9;7(32):51027-51043 [PMID: 27340921]
  86. Blood. 2009 Apr 30;113(18):4370-80 [PMID: 19131544]
  87. Cancer Res. 2014 Nov 1;74(21):6082-93 [PMID: 25205102]
  88. Int Immunol. 2009 Jul;21(7):843-58 [PMID: 19515798]
  89. J Exp Med. 1988 Mar 1;167(3):1016-33 [PMID: 3280724]
  90. Blood. 2006 Jan 15;107(2):716-24 [PMID: 16174765]
  91. Nature. 1981 Nov 19;294(5838):268-71 [PMID: 6272125]
  92. Exp Toxicol Pathol. 1993 Aug;45(4):233-8 [PMID: 8219713]
  93. Rinsho Ketsueki. 1995 Jun;36(6):573-7 [PMID: 7643453]
  94. Trends Biochem Sci. 2011 Dec;36(12):633-41 [PMID: 21975038]
  95. Retrovirology. 2015 Aug 20;12:73 [PMID: 26289727]
  96. Cancer Res. 2007 Dec 15;67(24):11859-66 [PMID: 18089816]
  97. Nat Med. 2006 Nov;12(11):1316-22 [PMID: 17057712]
  98. Blood. 2015 Dec 10;126(24):2570-7 [PMID: 26361794]
  99. J Virol. 2006 Nov;80(21):10683-91 [PMID: 16943297]
  100. Nature. 1989 Sep 7;341(6237):72-4 [PMID: 2788824]
  101. Blood. 2006 Jul 15;108(2):487-92 [PMID: 16410443]
  102. J Immunol. 1995 Jan 1;154(1):180-91 [PMID: 7995938]
  103. PLoS One. 2021 Aug 18;16(8):e0256320 [PMID: 34407152]
  104. Nat Med. 2007 May;13(5):527-8 [PMID: 17479090]
  105. PLoS Pathog. 2013 Sep;9(9):e1003630 [PMID: 24068936]
  106. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5 [PMID: 26396258]
  107. Blood. 2010 Nov 11;116(19):3802-8 [PMID: 20587783]
  108. J Virol. 2002 Sep;76(18):9389-97 [PMID: 12186921]
  109. Life Sci. 2019 Sep 1;232:116628 [PMID: 31278946]
  110. Blood Cancer J. 2013 Aug 16;3:e132 [PMID: 23955587]
  111. Nat Immunol. 2007 Jun;8(6):584-91 [PMID: 17468759]
  112. JCI Insight. 2019 Oct 3;4(19): [PMID: 31578308]
  113. Stem Cells. 2006 Mar;24(3):631-41 [PMID: 16210406]
  114. Blood. 2009 Sep 24;114(13):2709-20 [PMID: 19584402]
  115. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2438-43 [PMID: 9122213]
  116. Blood. 2005 Oct 1;106(7):2462-71 [PMID: 15956280]
  117. N Engl J Med. 1995 Jun 29;332(26):1749-51 [PMID: 7760891]
  118. Blood. 2009 Oct 1;114(14):2961-8 [PMID: 19657116]
  119. J Exp Med. 2009 Jan 16;206(1):25-34 [PMID: 19103877]
  120. J Biol Chem. 1994 Dec 16;269(50):31831-5 [PMID: 7989356]
  121. Int J Oncol. 2018 Oct;53(4):1681-1690 [PMID: 30066853]
  122. Science. 1992 Dec 11;258(5089):1792-5 [PMID: 1299224]
  123. J Vet Med Sci. 1994 Jun;56(3):601-3 [PMID: 7948404]
  124. Retrovirology. 2009 Jan 16;6:7 [PMID: 19146708]
  125. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [PMID: 16407133]
  126. PLoS Pathog. 2017 Jan 3;13(1):e1006120 [PMID: 28046066]
  127. Cancer Lett. 2012 Apr 28;317(2):218-25 [PMID: 22138435]
  128. Br J Haematol. 2015 May;169(3):356-67 [PMID: 25612920]
  129. Leuk Res. 2006 Jan;30(1):90-7 [PMID: 16002138]
  130. J Immunol. 1995 Aug 1;155(3):1588-98 [PMID: 7636219]
  131. Blood. 1997 Jul 15;90(2):783-94 [PMID: 9226179]
  132. Nature. 1983 Feb 10;301(5900):527-30 [PMID: 6823332]
  133. Nat Commun. 2017 Jun 22;8:15890 [PMID: 28639618]
  134. Science. 1991 Aug 30;253(5023):1026-8 [PMID: 1887217]
  135. Diabetes. 1993 Nov;42(11):1574-8 [PMID: 8405697]
  136. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7 [PMID: 20615947]
  137. Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749 [PMID: 32471947]
  138. PLoS Pathog. 2015 Aug 21;11(8):e1005120 [PMID: 26296091]
  139. Nature. 1988 Sep 15;335(6187):256-9 [PMID: 2970594]
  140. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [PMID: 7862633]
  141. Nat Med. 2006 Apr;12(4):466-72 [PMID: 16550188]
  142. Carcinogenesis. 2005 Aug;26(8):1382-8 [PMID: 15831528]
  143. Jpn J Cancer Res. 1992 Apr;83(4):320-3 [PMID: 1506264]
  144. Leukemia. 2004 Aug;18(8):1357-63 [PMID: 15190257]
  145. PLoS Pathog. 2011 Sep;7(9):e1002231 [PMID: 21909275]
  146. Blood. 2014 Jan 16;123(3):346-55 [PMID: 24196073]
  147. J Virol. 2000 May;74(10):4860-7 [PMID: 10775625]
  148. Blood. 1993 Aug 1;82(3):722-31 [PMID: 8338942]
  149. FEBS J. 2020 Sep;287(18):4005-4015 [PMID: 32027454]
  150. Int J Hematol. 2008 Dec;88(5):476-482 [PMID: 19039627]
  151. Blood. 2001 Feb 15;97(4):987-93 [PMID: 11159527]

MeSH Term

Adult
Mice
Humans
Animals
Leukemia-Lymphoma, Adult T-Cell
Human T-lymphotropic virus 1
Retroviridae Proteins
HTLV-I Infections
Mice, Transgenic
Disease Models, Animal
Basic-Leucine Zipper Transcription Factors

Chemicals

Retroviridae Proteins
Basic-Leucine Zipper Transcription Factors
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0HTLV-1ATLmicecellmouseTmodelsestablishedimmunodeficientAdultleukemiahumaninfectioninfection/ATLpathogenesisdeveloptransgenicusedmodeldifferentcharacteristicsTaxHBZhumanizedaggressivehematologicdiseasecausedvirustype1VariousanimalelucidateappropriatetreatmentsanalysesemployingmurinelowinfectivitymustconsidereduseresearchpurposesspontaneouslytumorsrolestransformationtumorgrowthSeverelyableengraftedlinespreclinicalstudiescandidatemoleculestreatmentHTLV-1-infectedimmunesystemsuitablecharacterizecellsearlystagesreviewoutlinesdescribesprogressmadeelucidatingdevelopingrelatedtherapiesusingMouseModelsInfectionCellLeukemia

Similar Articles

Cited By (3)